ABVC BioPharma Receives Additional $70,000 Payment Under Vitargus® Licensing Agreement

ABVC BioPharma has received a $70,000 licensing payment from partner ForSeeCon Eye Corporation under their global licensing agreement for Vitargus®, bringing cumulative payments to $566,000. The agreement carries potential value of up to $93.5 million including equity consideration, cash licensing payments, and future royalties. This financial support comes as ABVC positions itself to capitalize on the growing vitreous substitute market, which independent research estimates at $2.5 billion in 2024 and projects to reach $4.1 billion by 2033 according to market analysis available at https://www.verifiedmarketreports.com/product/vitreous-substitute-market/?utm_source=chatgpt.com.

Since the start of fiscal 2025, ABVC has received $1,345,950 in licensing revenues across all current partnerships. These revenues come with minimal incremental costs as development expenses were largely incurred in prior years, enabling the company to capture high-margin revenues that directly enhance its financial position while supporting strategic reinvestments. Management expects this favorable financial structure to continue supporting the company's operations and growth initiatives.

The company will allocate the new licensing income to its Good Manufacturing Practice pharmaceutical facility in Hsinchu, Taiwan, specifically preparing for GMP-compliant production of Vitargus®. This facility represents a critical milestone in moving the biodegradable vitreous substitute from development into scalable, regulatory-compliant manufacturing necessary for future commercialization. The strategic investment in manufacturing infrastructure demonstrates ABVC's commitment to advancing Vitargus® toward market readiness.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the significance of these developments, noting that the cumulative payments under the agreement now exceed half a million dollars. He highlighted that the high-margin revenues enable direct reinvestment into the Hsinchu GMP facility, where groundwork is being laid for Vitargus® GMP-compliant production. This step is critical for moving toward commercialization and delivering long-term shareholder value.

ABVC's licensing framework extends beyond ForSeeCon to include multiple partners such as AiBtl and OncoX, with potential future receivables exceeding $12 million. This diversified partnership approach positions the company to capture both near-term liquidity and long-term growth opportunities across central nervous system disorders, oncology, and ophthalmology. The company's broader pipeline includes six drugs and one medical device under development, utilizing technology licensed from prestigious research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.